FDA Inspection 1315968 — Astellas Pharma US Inc.
The FDA completed an inspection of Astellas Pharma US Inc. on Apr 3, 2026 in Northbrook, IL. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Apr 3, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Northbrook, IL (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)